Marker Therapeutics Inc
NASDAQ:MRKR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Marker Therapeutics Inc (MRKR) under the Base Case is 4.97 USD per share.
Compared with the current market price of 1.02 USD, the stock appears
Undervalued by 79% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Marker Therapeutics Does
Marker Therapeutics is a clinical-stage biotechnology company that develops cell-based immunotherapies for cancer. Its main idea is to train a patient’s own T cells to recognize several tumor targets at once, with the goal of helping the immune system find and attack cancer cells more effectively. The company’s lead programs focus on blood cancers, and it may also apply the same approach to other hard-to-treat tumors.
- Headquarters
- United States of America US
- Employees
- 5
- IPO date
- Nov 8, 2016
Revenue & Expenses Breakdown
Marker Therapeutics Inc
Earnings Waterfall
Marker Therapeutics Inc
What is the Intrinsic Value of one MRKR stock?
The intrinsic value for Marker Therapeutics Inc (MRKR) under the Base Case is 4.97 USD.
Is MRKR stock undervalued or overvalued?
Compared with the current market price of 1.02 USD, the stock appears Undervalued by 79% .
